12 completed, 3 terminated, 2 recruiting, 2 withdrawn. 22 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 22 | Completed 12, Terminated 3, Recruiting 2, Withdrawn 2, Active not recruiting 1, Not yet recruiting 1, Unknown 1 |
Follow Exocrine Pancreatic Insufficiency: new trials by email Literature Review of Exocrine Pancreatic Insufficiency trials Research Report on Exocrine Pancreatic Insufficiency
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Multicenter Clinical Study on Protein Absorption Efficiency in Patients With Pancreatic Exocrine Insufficiency in the ICU Short peptide, Protein - High-risk Patients With Pancreatic Exocrine Insufficiency, Enteral Nutrition Feeding | Phase 4 | Not yet recruiting | Shanghai 10th People's Hospital | 250 | 2026-07-01 | 2026-07-16 |
| Malabsorption Blood Test (MBT) to Determine Exocrine Pancreatic Function and Related Quality of Life in Chronic Pancreatitis Pancreatic Enzyme Replacement Therapy, Placebo, MBT1 - Chronic Pancreatitis, Recurrent Acute Pancreatitis | Phase 4 | Recruiting | Anna Evans Phillips | 80 | 2026-04-20 | 2026-09-11 |
| A Study Of Effect Of Secretin For In Injection (Chirostim) On Pancreatic Fluid Composition In Healthy Subjects Secretin (human synthetic) - ChiRhoClin - Exocrine Pancreatic Insufficiency, Chronic Pancreatitis | Phase 4 | Active not recruiting | Mayo Clinic | 24 | 2026-03-11 | 2026-10-26 |
| Safety of Stopping Pancreatic Enzyme Replacement Therapy in Children With Improved Pancreatic Function After Highly Effective Modulator Therapy Discontinuation of Pancreatic Enzyme Replacement Therapy - Cystic Fibrosis (CF), Pancreatic Insufficiency | Phase 4 | Completed | Indiana University | 17 | 2024-12-03 | 2026-07-02 |
| Pancreatic Enzyme Replacement Therapy for Acute Pancreatitis-Associated Exocrine Pancreatic Insufficiency Pancrelipase Capsules - Exocrine Pancreatic Insufficiency | Phase 4 | Recruiting | Ohio State University | 30 | 2024-02-01 | 2026-06-10 |
| The Effect of PERT on Patients Undergoing Pancreaticoduodenectomy Pancreatin Enteric-coated Capsules, Routine treatment plan - Pancreatic Exocrine Insufficiency, Pancreatic Enzyme Replacement Therapy | Phase 4 | Unknown | Ruijin Hospital | 100 | 2023-11-01 | 2023-11-07 |
| Study to Evaluate Symptoms of Exocrine Pancreatic Insufficiency in Adult Participants With Cystic Fibrosis or Chronic Pancreatitis Treated With Creon CREON - Cystic Fibrosis, Chronic Pancreatitis | Phase 4 | Completed | AbbVie | 30 | 2021-10-14 | 2024-07-23 |
| Study Of Effects Of Oral CREON Capsules In Adult Participants With Exocrine Pancreatic Insufficiency Not Due To Cystic Fibrosis, Chronic Pancreatitis, Pancreatectomy, Or Pancreatic Cancer CREON - Exocrine Pancreatic Insufficiency (EPI) | Phase 4 | Withdrawn | AbbVie | 2020-05-06 | 2021-11-08 | |
| A Study of Creon (Pancrelipase) in Resected and Non-resected Pancreatic Cancer Participants With Exocrine Pancreatic Insufficiency (EPI) Pancrelipase, Placebo - Exocrine Pancreatic Insufficiency (EPI) | Phase 4 | Terminated | AbbVie | 1 | 2020-02-25 | 2023-06-05 |
| A Study to Compare US Marketed Creon Manufactured With a Modernized Process at an Alternate Manufacturing Site and Manufactured With the Approved Manufacturing Process at an Alternate Active Pharmaceutical Ingredient Site, in Participants With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis Pancrelipase - Cystic Fibrosis | Phase 4 | Completed | AbbVie | 36 | 2019-10-23 | 2023-09-28 |
| EASY: Extended Access to Sollpura Over Years Liprotamase - Exocrine Pancreatic Insufficiency, Cystic Fibrosis | Phase 4 | Completed | Anthera Pharmaceuticals | 25 | 2016-09-01 | 2018-05-17 |
| A Study to Assess the Effect of Creon® on Pancreatic Exocrine Insufficiency in Subjects With Diabetes Mellitus Type 2 Creon, Creon 25000 matching Placebo - Exocrine Pancreatic Insufficiency in Subjects With Diabetes Mellitus Type 2 | Phase 4 | Withdrawn | Abbott | 2013-11-01 | 2014-06-20 | |
| Creon Use in Coeliac Patients With Low Faecal Pancreatic Elastase Creon, Placebo - Patients With Coeliac Disease and Chronic Diarrhoea (>3 Loose/ Liquid Motions a Day for More Than 4 Weeks), Patients With Pancreatic Exocrine Insufficiency | Phase 4 | Terminated | Sheffield Teaching Hospitals NHS Foundation Trust | 2 | 2013-05-01 | 2019-09-23 |
| Enzyme Suppletion in Exocrine Pancreatic Dysfunction Panzytrat 25.000 FIP-E units of Lipase - Chronic Pancreatitis, Exocrine Pancreatic Insufficiency | Phase 4 | Completed | Foundation for Liver Research | 10 | 2011-10-01 | 2015-03-11 |
| Control of Steatorrhea in Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency Panzytrat® 25,000, Kreon® 25,000 - Exocrine Pancreatic Insufficiency, Cystic Fibrosis | Phase 4 | Completed | Forest Laboratories | 87 | 2011-04-01 | 2014-04-10 |
| Irritable Bowel Syndrome Evaluation and Treatment in Primary Care Bifidobacterium infantis, Pancrelipase, Nitazoxanide - Irritable Bowel Syndrome | Phase 4 | Completed | American Academy of Family Physicians | 61 | 2010-11-01 | 2019-01-23 |
| PR-018: An Open-Label, Safety Extension of Study PR-011 EUR-1008 (APT-1008) - Cystic Fibrosis, Exocrine Pancreatic Insufficiency | Phase 4 | Completed | Forest Laboratories | 15 | 2010-07-01 | 2017-03-21 |
| A Study to Evaluate the Mode of Administration and Safety of EUR-1008 (APT-1008) in Infants 1 to 12 Months of Age EUR-1008 (APT-1008) - Cystic Fibrosis, Exocrine Pancreatic Insufficiency | Phase 4 | Completed | Forest Laboratories | 15 | 2010-06-01 | 2014-04-10 |
| Intraduodenal Aspiration Study to Assess the Bioavailability of Oral Pancrecarb® Compared to Placebo Control Pancrelipase - Exocrine Pancreatic Insufficiency, Chronic Pancreatitis | Phase 4 | Terminated | Digestive Care, Inc. | 3 | 2008-08-01 | 2013-02-22 |
| Creon After Pancreatic Surgery Creon, Placebo - Pancreatic Insufficiency | Phase 4 | Completed | Abbott Products | 58 | 2008-04-01 | 2011-08-18 |
Showing 20 of 22. Sign in to see all of them.
Cystic Fibrosis (9) · Pancreatitis, Chronic (6) · Diarrhea (1) · Irritable Bowel Syndrome (1) · Malabsorption Syndromes (1) · Malnutrition (1) · Pancreatic Diseases (1) · Pancreatic Neoplasms (1) · Pancreatitis (1) · Steatorrhea (1)
Digestive System Diseases (22) · Pancreatic Diseases (21) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (9) · Genetic Diseases, Inborn (9) · Infant, Newborn, Diseases (9) · Lung Diseases (9) · Respiratory Tract Diseases (9) · Pathological Conditions, Signs and Symptoms (7) · Chronic Disease (6) · Disease Attributes (6) · Pathologic Processes (6) · Pancreatitis (5) · Gastrointestinal Diseases (2) · Intestinal Diseases (2) · Colonic Diseases (1)
Pancrelipase (13) · Probiotics (1) · Proteins (1) · Secretin (1) · Sugars (1) · bifidus factor (1) · liprotamase lipase (1) · nitazoxanide (1) · pentadecanoic acid (1)
AbbVie (4) · Forest Laboratories (3) · Abbott (1) · Abbott Products (1) · American Academy of Family Physicians (1) · Anna Evans Phillips (1) · Anthera Pharmaceuticals (1) · Children's Hospital of Philadelphia (1) · Digestive Care, Inc. (1) · Foundation for Liver Research (1) · Hospital Avicenne (1) · Indiana University (1) · Mayo Clinic (1) · Ohio State University (1) · Ruijin Hospital (1)
United States (13) · Germany (3) · China (2) · Hungary (2) · Poland (2) · Spain (2) · Bulgaria (1) · Czechia (1) · Israel (1) · Italy (1) · Netherlands (1) · United Kingdom (1)
Anna E Phillips, MD MS (1) · David S Sanders, FRCP (1) · Gerard Mullin, MD (1) · Guenter Krause, MD (1) · Kim Brouwer, PharmD, PhD (1) · Lisa Gangarosa, M.D. (1) · Marco Bruno, MD, PhD (1) · Maria Mascarenhas, M.D. (1) · Robert Benamouzig, Pr (1) · Samuel Han, MD (1) · Suntje Sander-Struckmeier, PhD (1) · Wilson Pace, MD (1)
2005 (1), 2017 (1), R01DK140381 (1)